As at Feb 4, 2025, the ALKS stock has a PE ratio of 15.57. This is based on the current EPS of $2.01 and the stock price of $31.3 per share. An increase of 22% has been recorded in the P/E ratio compared to the average of 12.8 of the last 4 quarters.
The mean historical PE ratio of Alkermes over the last two years is 20.7. The current 15.57 PE ratio is 25% below the historical average. In the past two years, ALKS's PE ratio was at its highest in the Jun 2023 quarter at 51.31, with a price of $31.3 and an EPS of $0.61. The Mar 2024 quarter recorded the bottom point at 10.33, with a price of $27.07 and an EPS of $2.62.
Maximum annual increase: 23.6% in 2009
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2023 | 12.96 | N/A | $27.74 | $2.14 |
2022 | N/A | N/A | $26.13 | -$0.97 |
2021 | N/A | N/A | $23.26 | -$0.3 |
2020 | N/A | N/A | $19.95 | -$0.7 |
2019 | N/A | N/A | $20.4 | -$1.25 |
2018 | N/A | N/A | $29.51 | -$0.9 |
2017 | N/A | N/A | $54.73 | -$1.03 |
2016 | N/A | N/A | $55.58 | -$1.38 |
2015 | N/A | N/A | $79.38 | -$1.52 |
2014 | N/A | N/A | $58.56 | -$0.21 |
2013 | 124.74 | N/A | $23.7 | $0.19 |
2012 | N/A | N/A | $18.55 | -$0.99 |
2011 | N/A | N/A | $12.95 | -$0.48 |
2010 | N/A | N/A | $12.97 | -$0.42 |
2009 | 8.85 | 23.6% | $12.13 | $1.37 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Sep 2024 | 13.93 | 0% | $27.99 | $2.01 |
Jun 2024 | 13.93 | 34.85% | $24.1 | $1.73 |
Mar 2024 | 10.33 | -20.29% | $27.07 | $2.62 |
Dec 2023 | 12.96 | -40.3% | $27.74 | $2.14 |
Sep 2023 | 21.71 | -57.69% | $28.01 | $1.29 |
Jun 2023 | 51.31 | N/A | $31.3 | $0.61 |
Mar 2023 | N/A | N/A | $28.19 | -$1 |
Dec 2022 | N/A | N/A | $26.13 | -$0.97 |
Sep 2022 | N/A | N/A | $22.33 | -$0.78 |
Jun 2022 | N/A | N/A | $29.79 | -$0.57 |
Mar 2022 | N/A | N/A | $26.31 | -$0.38 |
Dec 2021 | N/A | N/A | $23.26 | -$0.3 |
Sep 2021 | N/A | N/A | $30.84 | -$0.58 |
Jun 2021 | N/A | N/A | $24.52 | -$0.4 |
Mar 2021 | N/A | N/A | $18.68 | -$0.6 |
ALKS's current P/E ratio is lower than the 3, 5 and 10-year averages.
ALKS's PE ratio is lower than its peer stocks JNJ and AZN. Alkermes is presently trading at a lower PE ratio (15.57) than its peer group average of 27.58.
Stock name | PE ratio | Market cap |
---|---|---|
ALKS Alkermes plc | 15.57 | $5.06B |
NVS Novartis AG | 17.82 | $208.31B |
JNJ Johnson & Johnson | 25.45 | $369.55B |
AZN Astrazeneca plc | 33 | $213.78B |
PFE Pfizer Inc | 34.04 | $146.61B |
BMY Bristol Myers Squibb Co | N/A | $119.91B |
TEVA Teva Pharmaceutical Industries Ltd | N/A | $19.33B |
The price to earnings ratio for ALKS stock as of Feb 4, 2025, stands at 15.57.
As an average over the last 3 years, ALKS stock has a PE ratio of 20.7.
As an average over the last 5 years, ALKS stock has a PE ratio of 20.7.
The highest quarterly PE ratio in the last two years has been 51.31 and it was in the Jun 2023 quarter.
ALKS's current price to earnings ratio is 25% below its 2-year historical average.
The PE ratio is calculated by dividing the most recent price of a stock by its trailing twelve months EPS. As of today (Feb 4, 2025), Alkermes's stock price is $31.3. The earnings per share for the trailing twelve months (TTM) ending Sep 2024 is $2.01. Therefore, Alkermes's P/E ratio for today is 15.57. PE RATIO(15.57) = STOCK PRICE($31.3) / TTM EPS($2.01)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.